Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496453 | 1.00 | ADORA2A (0.39) | ADORA2ABCHEYTHDC1SMN1; SMN2TSHR | |
| SCHEMBL183167 | 0.83 | YTHDC1 (0.47) | ADORA2AYTHDC1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL29601245 | 0.83 | YTHDC1 (0.47) | ADORA2AYTHDC1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL3422012 | 0.79 | ADORA2A (0.51) | ADORA2AYTHDC1TSHRCYP2D6CYP2C9 | |
| SCHEMBL3426471 | 0.78 | SMN1; SMN2 (0.48) | ADORA2ASMN1; SMN2ALDH1A1GAAMAPK14 | |
| SCHEMBL9928488 | 0.76 | DGAT1 (0.36) | — | |
| SCHEMBL31138390 | 0.76 | DGAT1 (0.36) | — | |
| SCHEMBL30496448 | 0.76 | CYP11B1 (0.50) | YTHDC1SMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL21883488 | 0.76 | CYP11B1 (0.50) | YTHDC1SMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL8306393 | 0.75 | CNOT7 (0.34) | SMN1; SMN2CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-12157739-B2 | Hypoxanthine compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-12-03 | — | — | US | disclosed |
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-3819299-A1 | HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819299-A1 | HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-112673008-A | Hypoxanthine compound | 橘生药品工业株式会社 | 2021-04-16 | — | — | CN | disclosed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | ADORA2A 3048/4885BCHE 139/4885YTHDC1 4385/4885 |
| US-12157739-B2 | Hypoxanthine compounds | HPRT1, APRT, IMPDH1 | ADORA2A 1186/4885BCHE 2485/4885YTHDC1 651/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | ADORA2A 3225/4885BCHE 16/4885YTHDC1 4018/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | ADORA2A 2893/4885BCHE 71/4885YTHDC1 4747/4885 |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | ADORA2A 2752/4885BCHE 61/4885YTHDC1 4771/4885 |
| US-20210214357-A1 | HYPOXANTHINE COMPOUNDS | HPRT1, DHPS, PAH | ADORA2A 2291/4885BCHE 3074/4885YTHDC1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.